LT 1001

Drug Profile

LT 1001

Alternative Names: Sebocoyl dinalbuphine ester

Latest Information Update: 24 Jul 2015

Price : $50

At a glance

  • Originator Lumosa Therapeutics
  • Class Analgesics; Esters; Ethers; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Pain

Most Recent Events

  • 01 Apr 2015 Lumosa Therapeutics completes a phase II/III trial in Pain in Taiwan (NCT02468128)
  • 01 Apr 2015 Lumosa Therapeutics completes a phase I trial in Pain in Taiwan (NCT02446301)
  • 01 Jan 2015 Phase-I clinical trials in Pain in Taiwan (IM) (NCT02446301)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top